- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03005704
Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets (REVSTARTS)
Study Overview
Status
Intervention / Treatment
Detailed Description
Ticagrelor is one of three commercially available antiplatelet adenosine diphosphate (ADP) antagonists (the other two are clopidogrel and prasugrel). They exert their antiplatelet effects by binding to P2Y12 receptors on the platelet surface. Ticagrelor is used in combination with aspirin to prevent and treat thrombosis in patients with acute coronary syndrome, particularly after stent implantation. ADP antagonists are combined with aspirin because aspirin blocks platelet aggregation by preventing thromboxane production, and blocking two different pathways leads to greater efficacy than either drug used alone. Recent clinical trials indicate ticagrelor in combination with aspirin is more effective for prevention of thrombotic events in patients with symptomatic coronary artery disease than aspirin in combination with clopidogrel, but causes significantly more bleeding. The improved efficacy and reduced safety occurs because ticagrelor causes greater inhibition of ADP-mediated platelet activation. The latter can be reliably measured in the laboratory.
Management of patients who bleed while taking an ADP antagonist in combination with aspirin is challenging because there is no specific antidote, Platelet transfusion has the potential to reverse the effects of clopidogrel or prasugrel and aspirin, but these findings cannot be extrapolated to ticagrelor in combination with aspirin because the pharmacokinetic and pharmacodynamic effects of ticagrelor differ.
Aspirin, clopidogrel active metabolite, and prasugrel active metabolite have half-lives of 15-20 minutes, 30 minutes, and four hours respectively. They are irreversible platelet inhibitors which bind to and permanently block platelet function. After their drug elimination, new platelets which enter the circulation from megakaryocytes in the bone marrow are unaffected. Therefore, after elimination, newly transfused platelets have the potential to restore haemostasis. In contrast, ticagrelor, a reversible platelet inhibitor, has a longer half-life (7.7 to 14.1 hours). As a result of its longer half-life, newly added platelets (both from the bone marrow and transfused platelets) are inhibited by ticagrelor for at least 24 hours after the last dose. Therefore, reversing platelet inhibition and controlling excessive bleeding associated with ticagrelor by platelet transfusion poses a greater challenge than with clopidogrel and prasugrel. Nevertheless, because of its greater efficacy, ticagrelor is preferred over clopidogrel in high risk patients.
Previous studies of platelet transfusion and ev vivo mixing within 24 hours of drug administration have shown than the inhibition of ADP-mediated platelet activation by clopidogrel and prasugrel, but not ticagrelor can be reversed or modulated by the addition of donor platelets. Although reversing the platelet inhibitory effects of ticagrelor might not be possible within 24 hours of stopping the drug, it should be possible in the days that follow. This has not been examined. Accordingly, we propose to perform a study in which we systematically evaluate inhibition of ADP mediated platelet activation, a reliable measure of ticagrelor's antiplatelet activity, when donor platelets are added to the platelets of subjects treated with ticagrelor at time intervals up to 96 hours after their last dose.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L9L 2X2
- Recruiting
- Population Health Research Institute
-
Contact:
- Paul Kruger, MB BS
- Phone Number: 9059230285
- Email: paul.kruger@phri.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy subjects
- At least 18 years of age
- No history of cardiovascular disease
- Not taking antiplatelet therapy prior to participation
Exclusion Criteria:
- Known thrombocytopenia, other coagulation disorder such as von Willebrand's disease, haemophilia
- Allergy or intolerance to ticagrelor or aspirin (if known)
- Consumption of drugs within the preceding fourteen days that potentially can interfere with metabolism of ticagrelor through CYP3A4, CYP3A or P-glycoprotein (eg, ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir, diltiazem, amprenavir, aprepitant, erythromycin, fluconazole, verapamil, rifampicin, dexamethasone, phenytoin, carbamazepine, phenobarbital, cyclosporine, simvastatin, atorvastatin, tolbutamide, digoxin)21
- Previous transfusion or pregnancy (because of potential alloimmunisation)
- Pregnant or trying to conceive, or breastfeeding
- Unable or unwilling to give written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Antiplatelet Treatment
Subjects will be treated with five days of ticagrelor in combination with acetylsalicylic acid.
|
Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days.
Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose.
Acetylsalicylic acid will be administered at a dose of 81 mg daily.
Other Names:
|
No Intervention: Control
Subjects will not receive antiplatelet treatment and their PRP will be used as the source of untreated platelets in laboratory mixing studies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reversal of platelet inhibition
Time Frame: 5 days
|
The primary outcome is to measure the efficacy of untreated platelets in reversing the platelet inhibition due to ticagrelor in combination with aspirin by ex vivo mixing studies.
Increase in platelet aggregation will be measured by light transmission aggregometry after stimulation by adenosine diphosphate, arachidonic acid, and collagen.
|
5 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Timing of reversal of platelet inhibition
Time Frame: 5 days
|
The secondary outcome measure is to determine the time point post cessation at which untreated donor platelets reverse the antiplatelet effect of ticagrelor in combination with aspirin.
|
5 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Aspirin
- Ticagrelor
Other Study ID Numbers
- PopulationHRI
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aspirin
-
University of PennsylvaniaBayer; National Institutes of Health (NIH)CompletedAspirin Resistance | Pharmacological Aspirin Non-responsiveness
-
Hamilton Health Sciences CorporationCompleted
-
Northwell HealthStaten Island University HospitalCompletedAspirin Resistance
-
University of Lausanne HospitalsCompletedAspirin ResistanceSwitzerland
-
Azienda Ospedaliera San Giovanni BattistaUnknown
-
Chinese University of Hong KongUnknownAspirin | MicrobiotaHong Kong
-
BayerCompletedAspirin | Drug Safety | Effects, LongtermGermany
-
Cardiff UniversityCompletedPlatelet Dysfunction Due to AspirinUnited Kingdom
-
George Washington UniversityCompletedPlatelet Dysfunction Due to AspirinUnited States
-
Stephane CookCompletedAspirin Causing Adverse Effects in Therapeutic UseSwitzerland
Clinical Trials on Antiplatelet treatment
-
Josep Rodes-CabauRecruitingIschemic Stroke | Patent Foramen Ovale | Bleeding UlcerCanada
-
Centre Hospitalier Universitaire de Saint EtienneNot yet recruiting
-
Institute of Cardiology, Warsaw, PolandMedical Research Agency, PolandRecruitingAtrial FibrillationPoland
-
National Institute of Cardiology, Warsaw, PolandMedical Research Agency, PolandRecruitingAtrial FibrillationPoland
-
Seoul National University HospitalLudwig-Maximilians - University of Munich; ST. Antonius hospital NieuwegeinRecruitingCoronary Artery Disease | Acute Coronary SyndromeKorea, Republic of
-
State University of New York - Upstate Medical...CompletedIschemic Stroke | TIAUnited States
-
Xueli CaiRecruitingStroke | Thrombectomy | Tandem OcclusionChina
-
Seoul St. Mary's HospitalAstraZeneca; The Catholic University of Korea; Chonnam National UniversityUnknownBleeding | Percutaneous Coronary Intervention | Acute Myocardial Infarction | Major Adverse Cardiovascular EventsKorea, Republic of
-
Sichuan Provincial People's HospitalRecruitingIschemic Stroke | Antiplatelet DrugChina
-
Tufts Medical CenterDialysis Clinic, Inc.WithdrawnChronic Kidney Disease